27872
document
Risperidone in children with autism : randomized , placebo-controlled , double-blind study . Some open-label studies suggest that risperidone can be useful in the treatment of certain target symptoms in children with autism . We aimed to study whether the use of risperidone in comparison with placebo improved functioning in children with autism with regard to behavior ( aggressiveness , hyperactivity , irritability ) , social and emotional responsiveness , and communication skills . We conducted a randomized , double-blind , placebo-controlled trial with 40 consecutive children with autism , whose ages ranged from 2 to 9 years , who were receiving either risperidone or placebo given orally at a dose of 1 mg/day for 6 months . Autism symptoms were monitored periodically . The outcome variables were total scores on the Childhood Autism Rating Scale ( CARS ) and the Children 's Global Assessment Scale ( CGAS ) after 6 months . Of the 40 children enrolled , 39 completed the trial over a period of 18 months ; 19 received risperidone , and 20 received placebo . In the risperidone group , 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children 's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children 's Global Assessment Scale score in the placebo group ( P < .001 and P = .035 , respectively ) . Risperidone also improved social responsiveness and nonverbal communication and reduced the symptoms of hyperactivity and aggression . Risperidone was associated with increased appetite and a mild weight gain , mild sedation in 20 % , and transient dyskinesias in three children . Risperidone improved global functioning and social responsiveness while reducing hyperactivity and aggression in children with autism and was well tolerated .
27873
Intervention_Pharmacological
Risperidone
27874
Intervention_Pharmacological
risperidone
27875
Intervention_Pharmacological
risperidone
27876
Intervention_Control
placebo
27877
Intervention_Control
placebo-controlled
27878
Intervention_Pharmacological
risperidone
27879
Intervention_Control
placebo
27880
Intervention_Pharmacological
risperidone
27881
Intervention_Control
placebo
27882
Intervention_Pharmacological
risperidone
27883
Intervention_Control
placebo
27884
Intervention_Pharmacological
Risperidone
27885
Intervention_Pharmacological
Risperidone
27886
Intervention_Pharmacological
Risperidone
27887
Outcome_Physical
total
27888
Outcome_Mental
Childhood Autism Rating Scale
27889
Outcome_Physical
score
27890
Outcome_Mental
Children 's Global Assessment Scale score
27891
Outcome_Mental
Childhood Autism Rating Scale score
27892
Outcome_Mental
Children 's Global Assessment Scale score
27893
Outcome_Mental
social responsiveness
27894
Outcome_Other
and
27895
Outcome_Mental
nonverbal communication
27896
Outcome_Physical
symptoms of
27897
Outcome_Mental
hyperactivity
27898
Outcome_Physical
and
27899
Outcome_Mental
aggression
27900
Outcome_Physical
.
27901
Outcome_Physical
appetite
27902
Outcome_Physical
weight gain
27903
Outcome_Physical
mild sedation
27904
Outcome_Physical
transient dyskinesias
27905
Outcome_Mental
global functioning
27906
Outcome_Mental
social responsiveness
27907
Outcome_Physical
reducing
27908
Outcome_Mental
hyperactivity
27909
Outcome_Physical
and
27910
Outcome_Mental
aggression
27911
Participant_Age
children
27912
Participant_Condition
autism
27913
Participant_Age
children
27914
Participant_Condition
autism
27915
Participant_Age
children
27916
Participant_Condition
autism
27917
Participant_Sample-size
40
27918
Participant_Age
children
27919
Participant_Condition
autism
27920
Participant_Age
ages ranged from 2 to 9 years
27921
Participant_Sample-size
40
27922
Participant_Age
children
27923
Participant_Age
children
27924
Participant_Condition
autism